Latest Filings

Issuer Activity

Insider Overview :: Stem Cell Therapeutics Corp. (V:SSS) [?]
Business Focus: Biopharmaceuticals
Recent Price for SSS
CAD 0.155 +0.01 (+6.90%)
TSXV Delayed 15 minutes
May 22 1040 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
0.155 0.600 0.0 13,300 6.59
1-Day Low 52-Week Low Yield Avg. Volume  
0.145 0.140 0.0% 136,916  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for SSS within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 21st, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 29/13 Apr 23/13 Allan, David G. P. Indirect Ownership Common Shares 10 - Acquisition in the public market 600 $0.180
Apr 29/13 Apr 23/13 Allan, David G. P. Indirect Ownership Common Shares 10 - Acquisition in the public market 500 $0.175
Apr 29/13 Apr 23/13 Allan, David G. P. Indirect Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.170
May 13/13 Apr 9/13 Uger, Robert Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
May 13/13 Apr 9/13 Petrova, Penka Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Apr 16/13 Apr 9/13 Peterson, Ronald Dean Direct Ownership Options 50 - Grant of options 100,000  
May 13/13 Apr 8/13 DeMesa, James Michael Direct Ownership Options 50 - Grant of options 100,000  
May 13/13 Apr 8/13 Uger, Robert Direct Ownership Options 50 - Grant of options 255,028  
May 13/13 Apr 8/13 Petrova, Penka Direct Ownership Options 50 - Grant of options 127,514  
May 13/13 Apr 8/13 Stiernholm, Bjorn Johan Niclas Direct Ownership Options 50 - Grant of options 1,275,141  
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for SSS within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 21st, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 13/13 Apr 8/13 DeMesa, James Michael Direct Ownership Options 50 - Grant of options 100,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation 40,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation 20,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation 3,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation 12,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation -400,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation -200,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation -30,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 37 - Stock split or consolidation -120,000  
May 13/13 Feb 6/13 DeMesa, James Michael Direct Ownership Options 52 - Expiration of options -62,500  
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for SSS on May 21, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
David G. Allan
Non-Independent Executive Chairman of the Board 		James T. Parsons
Chief Financial Officer 		 
Company Contact
Address: Suite 120-D, 101 College Street
TORONTO ON M5G 1L7
Tel: 1-647-2584325
Website: www.stemcellthera.com
IR: www.stemcellthera.com/IR.aspx
Business Overview
Stem Cell Therapeutics Corp. (SCT) is a development-stage company. The Company is focused on the development and commercialization of stem cell therapeutic technologies. SCT is developing stem cell-based therapies for cell therapy and regenerative medicine from academic sources for the purpose of commercialization. The Company's technology is a drug-based therapy that utilizes drugs to stimulate a patient's own resident adult stem cells. SCT's NTx-265 product targets the treatment of neurological conditions, such as stroke or traumatic brain injury by repurposing two drugs, human Chorionic Gonadotropin (hCG) and Erythropoietin (EPO). The Company's portfolio supports the expansion of these neurological treatments into diseases, such as multiple sclerosis (MS). On April 28, 2011, the Company announced the enrolment of first patient in the traumatic brain injury trial. On February 4, 2013, the Company completed its merger with Trillium Therapeutics Inc. (Trillium).
Competitors with Recent Insider Filings
Cardiome Pharma (T:COM)
Transition Therapeutics (T:TTH)
 
Stem Cell Therapeutics Corp. Insider Report Only $20.00